Are Investors Undervaluing Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) By 30%?

Published on 23 Dec 2024 on Simply Wall St. · via Yahoo Finance

(NASDAQ:IONS) by taking the expected future cash flows and discounting them to today's value. One...

Read the rest of the article

Start tracking your investments with Statfolio

(NASDAQ:IONS) by taking the expected future cash flows and discounting them to today's value. One...

Simply Wall St. · via Yahoo Finance 23 Dec 2024

On Thursday, the FDA approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Tryngolza (olezarsen) a...

Benzinga · via Yahoo Finance 21 Dec 2024

The FDA's nod to IONS' Tryngolza makes it the first approved treatment for FCS. It is also the...

Zacks · via Yahoo Finance 20 Dec 2024

Valued at around $11.95 million, the firm's ARK Innovation ETF and ARK Genomic Revolution ETF...

GuruFocus.com · via Yahoo Finance 20 Dec 2024

Cathie Wood-led Ark Invest made notable trades on Wednesday, involving Tesla Inc. (NASDAQ:TSLA) a...

Benzinga · via Yahoo Finance 20 Dec 2024

, opens new tab drug to treat a rare genetic disorder, making it the company's first wholly-owned...

Reuters 20 Dec 2024

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug...

WMBD - FOX 43 Peoria 20 Dec 2024

The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare ge...

Reuters 20 Dec 2024

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, w...

Insider Monkey · via Yahoo Finance 21 Nov 2024

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we ...

Insider Monkey · via Yahoo Finance 19 Nov 2024